ペプチドは安全か：臨床研究の結果

Review

Antimicrobial Peptides Show Promise as Cancer Therapeutics: A 2026 Systematic Review

A new review in Frontiers in Medicine evaluates antimicrobial peptides (AMPs) as anticancer agents, finding selective cytotoxicity against tumor cells via membrane disruption and apoptosis induction, though clinical evidence remains limited to early-phase trials.

Pemvidutide Achieves MASH Resolution in Phase 2b IMPACT Trial

The Lancet published Phase 2b results for pemvidutide, a dual GLP-1/glucagon agonist, showing significant MASH resolution without worsening fibrosis at 24 weeks. FDA granted Breakthrough Therapy designation in January 2026.

Retatrutide Achieves 28.7% Weight Loss in TRIUMPH-4 Phase 3 Trial

Eli Lilly's triple GIP/GLP-1/glucagon agonist retatrutide achieved an average 28.7% body weight reduction at 68 weeks in the pivotal TRIUMPH-4 trial — the largest weight loss ever reported for any anti-obesity medication in Phase 3.

Informational

ペプチドとは何か：体内での仕組みと効果を徹底解説

ペプチドとはアミノ酸が2〜50個程度結合した化合物で、ホルモン・神経伝達物質・抗菌因子として体内で多彩な役割を果たします。本記事では、ペプチドの基本構造、体内での作用メカニズム、医薬品・サプリメントとしての活用、そしてPMDAによる日本独自の規制と市販後調査についてわかりやすく解説します。

Ambrosia Biosciences Raises $100M to Develop Small-Molecule GLP-1 Pills That Could Replace Injections

Colorado-based Ambrosia Biosciences closed an oversubscribed $100M Series B to advance oral small-molecule GLP-1 therapies for obesity, aiming to move beyond peptide-based injections like Ozempic and Mounjaro with a Phase 1 trial of its lead candidate.

Clinical

APhA 2026: Pharmacists Say GLP-1 Therapies Are Rewriting the Rules of Metabolic Disease

At the 2026 American Pharmacists Association Annual Meeting in Los Angeles, experts presented evidence that GLP-1 receptor agonists have expanded far beyond diabetes into cardiovascular, liver, and kidney disease — challenging pharmacists to keep pace.

Daiichi Sankyo Partners With Meddenovo to Use AI for Designing Cyclic Peptide Drug Candidates

Japanese pharma giant Daiichi Sankyo has partnered with AI drug design company Meddenovo to accelerate the discovery of cyclic peptide-based therapeutics using AI and physical computational approaches, signaling growing industry interest in the peptide modality beyond GLP-1.

Neuland Laboratories to Open $30M Commercial Peptide Manufacturing Facility in India

India-based CDMO Neuland Laboratories will open a commercial-scale peptide manufacturing facility at its Hyderabad campus in summer 2026, adding 6,370 liters of synthesis capacity to meet surging global demand driven by the GLP-1 boom.